CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ®, its ...

CRISPR-Cas9 removed an extra chromosome 21 from some Down syndrome cells in the lab. Learn what the 30.6% result means and ...

Most of any gains (or lack thereof) from here will be driven by just three factors.

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical ...

CRISPR halves model-generation time and cuts costs by ~40%, while automation, aquatic models, genetic testing and cryobanking boost efficiency and client retention.Dublin, Oct. 07, 2026 (GLOBE ...

A single intravenous infusion of an experimental CRISPR-Cas9 therapy cut LDL cholesterol by 52.5% in patients who received ...

A single dose of an experimental CRISPR therapy cut LDL cholesterol and triglycerides by about half in patients with difficult-to-treat lipid disorders. The reductions were still present one year ...

In a small first-in-human trial, a single CRISPR-Cas9 infusion that switches off the ANGPTL3 gene in the liver kept LDL ...

Nabsys 2.0, LLC ("Nabsys"), a pioneer in Electronic Genome Mapping (EGM), today announced the publication of a new preprint demonstrating that CRISPR/Cas9 can be used to customize how EGM identifies ...

ZUG, Switzerland, BOSTON - CRISPR Therapeutics (Nasdaq: CRSP), announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited ...